James Pursley Sells 33,000 Shares of Hinge Health (NYSE:HNGE) Stock

Hinge Health Inc. (NYSE:HNGE) President James Pursley sold 33,000 shares of the firm’s stock in a transaction on Monday, June 22nd. The shares were sold at an average price of $69.31, for a total transaction of $2,287,230.00. Following the completion of the transaction, the president directly owned 740,897 shares of the company’s stock, valued at approximately $51,351,571.07. This trade represents a 4.26% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

James Pursley also recently made the following trade(s):

• On Tuesday, May 26th, James Pursley sold 16,000 shares of Hinge Health stock. The stock was sold at an average price of $53.79, for a total transaction of $860,640.00.

Hinge Health Stock Down 0.0%

Hinge Health stock opened at $70.36 on Thursday. Hinge Health Inc. has a 52-week low of $30.08 and a 52-week high of $72.39. The firm’s fifty day moving average is $55.45 and its 200 day moving average is $47.16. The company has a market cap of $5.44 billion and a price-to-earnings ratio of -5.70.

Hinge Health (NYSE:HNGE) last issued its quarterly earnings data on Tuesday, May 5th. The company reported $0.45 EPS for the quarter, topping analysts’ consensus estimates of $0.12 by $0.33. The business had revenue of $182.31 million during the quarter. Hinge Health had a negative net margin of 78.95% and a negative return on equity of 310.62%. The business’s quarterly revenue was up 47.2% on a year-over-year basis. During the same period in the previous year, the business earned $1.30 earnings per share. On average, equities research analysts anticipate that Hinge Health Inc. will post 1.33 earnings per share for the current fiscal year.

More Hinge Health News

Here are the key news stories impacting Hinge Health this week:

• Positive Sentiment: Hinge Health raised its Q2 2026 revenue guidance to $200 million-$202 million, above the Street’s $195 million estimate, and lifted full-year 2026 revenue guidance to $818 million-$824 million versus consensus of $801.6 million, signaling stronger growth expectations.
• Positive Sentiment: The stock continues to benefit from strong prior operating results, including revenue growth of 47.2% in the most recent reported quarter and earnings that beat analyst estimates, which supports the bullish analyst backdrop.
• Neutral Sentiment: Several analysts remain constructive on Hinge Health, with recent price targets in the $79-$90 range and a consensus rating of “Moderate Buy,” suggesting Wall Street still sees upside from current levels.
• Negative Sentiment: Major shareholder Insight Holdings Group sold a large block of shares in multiple June transactions, including 390,917 shares on June 24, 224,399 shares on June 22, and 112,477 shares on June 23, which can weigh on sentiment even though the sales were made under a pre-arranged 10b5-1 plan.
• Negative Sentiment: President James Pursley also sold 33,000 shares on June 22, adding to the cluster of insider selling that may raise concern about valuation after the stock’s recent run-up.

Wall Street Analysts Forecast Growth

Several brokerages have weighed in on HNGE. Piper Sandler reissued an “overweight” rating on shares of Hinge Health in a research note on Wednesday, June 10th. Truist Financial boosted their target price on Hinge Health from $79.00 to $85.00 and gave the company a “buy” rating in a research report on Thursday, June 11th. Zacks Research upgraded Hinge Health from a “hold” rating to a “strong-buy” rating in a report on Wednesday, May 13th. Barclays raised their price target on Hinge Health from $62.00 to $70.00 and gave the stock an “overweight” rating in a research report on Thursday, June 11th. Finally, Evercore reaffirmed an “outperform” rating and set a $45.00 price objective on shares of Hinge Health in a research note on Wednesday, April 8th. Two research analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Hinge Health currently has an average rating of “Moderate Buy” and an average price target of $75.80.

Institutional Trading of Hinge Health

A number of large investors have recently made changes to their positions in HNGE. Wells Fargo & Company MN grew its holdings in shares of Hinge Health by 160.0% in the fourth quarter. Wells Fargo & Company MN now owns 546 shares of the company’s stock worth $25,000 after purchasing an additional 336 shares during the last quarter. Caitong International Asset Management Co. Ltd bought a new stake in Hinge Health during the 4th quarter valued at about $26,000. CENTRAL TRUST Co bought a new stake in Hinge Health during the 1st quarter valued at about $37,000. First Horizon Corp boosted its position in Hinge Health by 163.9% in the 4th quarter. First Horizon Corp now owns 855 shares of the company’s stock valued at $40,000 after buying an additional 531 shares during the period. Finally, High Point Wealth Management LLC purchased a new stake in Hinge Health in the 4th quarter valued at about $46,000.

About Hinge Health

Hinge Health (NYSE: HNGE) is a digital musculoskeletal (MSK) clinic that provides end-to-end solutions for the prevention and management of musculoskeletal conditions. The company’s platform combines wearable motion sensors, personalized exercise therapy guided by licensed physical therapists, and behavioral health coaching to deliver tailored treatment plans. By integrating technology with evidence-based clinical protocols, Hinge Health aims to reduce pain, improve mobility and decrease reliance on more invasive interventions such as surgery or opioid prescriptions.

Founded in 2015 and headquartered in San Francisco, Hinge Health partners with employers, health plans and other payers to offer its self-directed, app-based programs.